▼ 0.11%
prev close
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Congressional Trades
20
All tracked trades
Members Trading
13
Unique members
Net Activity
-8
6 buys · 14 sells
Members Who Traded This Stock
20 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2025-12-19 | BMYBristol-Myers Squibb Co. | Buy | $1,001 - $15,000 | 142d ago | — | |
| 2025-12-18 | BMYBristol-Myers Squibb Co. | Sell | $1,001 - $15,000 | 139d ago | — | |
| 2025-11-13 | BMYBristol-Myers Squibb Co. | Sell | $1,001 - $15,000 | 174d ago | — | |
| 2025-11-12 | BMYBristol-Myers Squibb Co. | Buy | $1,001 - $15,000 | 170d ago | — | |
| 2025-05-12 | BMYBristol-Myers Squibb Co. | Sell | $15,001 - $50,000 | 346d ago | — | |
| 2025-04-28 | BMYBristol-Myers Squibb Co. | Sell | $1,001 - $15,000 | 141d ago | — | |
| 2025-04-15 | BMYBristol-Myers Squibb Co. | Sell | $1,001 - $15,000 | 384d ago | — | |
| 2025-04-01 | BMYBristol-Myers Squibb Co. | Sell | $1,001 - $15,000 | 385d ago | — | |
| 2025-03-27 | BMYBristol-Myers Squibb Co. | Sell | $1,001 - $15,000 | 421d ago | — | |
| 2025-01-15 | BMYBristol-Myers Squibb Co. | Buy | $1,001 - $15,000 | 476d ago | — | |
| 2024-10-29 | BMYBristol-Myers Squibb Co. | Buy | $1,001 - $15,000 | 264d ago | — | |
| 2024-01-18 | BMYBristol-Myers Squibb Co. | Sell | $1,001 - $15,000 | 639d ago | — | |
| 2023-09-26 | BMYBristol-Myers Squibb Co. | Buy | $1,001 - $15,000 | 937d ago | — | |
| 2023-03-07 | BMYBristol-Myers Squibb Co. | Sell | $1,001 - $15,000 | 1143d ago | — | |
| 2022-03-16 | BMYBristol-Myers Squibb Co. | Sell | $1,001 - $15,000 | 1506d ago | — | |
| 2021-11-10 | BMYBristol-Myers Squibb Co. | Sell | $15,001 - $50,000 | 1370d ago | — | |
| 2021-06-07 | BMYBristol-Myers Squibb Co. | Sell | $1,001 - $15,000 | 1262d ago | — | |
| 2020-07-10 | BMYBristol-Myers Squibb Co. | Sell | $1,001 - $15,000 | 1262d ago | — | |
| 2019-04-08 | BMYBristol-Myers Squibb Co. | Sell | $1,001 - $15,000 | 1262d ago | — | |
| 2018-04-17 | BMYBristol-Myers Squibb Co. | Buy | $1,001 - $15,000 | 1262d ago | — |
2025-12-19
Gilbert Cisneros
BMY
Amount
$1,001 - $15,000
Filed
142d ago
2025-12-18
Julie Johnson
BMY
Amount
$1,001 - $15,000
Filed
139d ago
2025-11-13
Julie Johnson
BMY
Amount
$1,001 - $15,000
Filed
174d ago
2025-11-12
Gilbert Cisneros
BMY
Amount
$1,001 - $15,000
Filed
170d ago
2025-05-12
Jefferson Shreve
BMY
Amount
$15,001 - $50,000
Filed
346d ago
2025-04-28
Julia Letlow
BMY
Amount
$1,001 - $15,000
Filed
141d ago
2025-04-15
Tommy Tuberville
BMY
Amount
$1,001 - $15,000
Filed
384d ago
2025-04-01
Julie Johnson
BMY
Amount
$1,001 - $15,000
Filed
385d ago
2025-03-27
Greg Landsman
BMY
Amount
$1,001 - $15,000
Filed
421d ago
2025-01-15
Julie Johnson
BMY
Amount
$1,001 - $15,000
Filed
476d ago
2024-10-29
Valerie Hoyle
BMY
Amount
$1,001 - $15,000
Filed
264d ago
2024-01-18
John James
BMY
Amount
$1,001 - $15,000
Filed
639d ago
2023-09-26
Greg Stanton
BMY
Amount
$1,001 - $15,000
Filed
937d ago
2023-03-07
Daniel Goldman
BMY
Amount
$1,001 - $15,000
Filed
1143d ago
2022-03-16
John Rutherford
BMY
Amount
$1,001 - $15,000
Filed
1506d ago
2021-11-10
Carol Devine Miller
BMY
Amount
$15,001 - $50,000
Filed
1370d ago
2021-06-07
Thomas Suozzi
BMY
Amount
$1,001 - $15,000
Filed
1262d ago
2020-07-10
Thomas Suozzi
BMY
Amount
$1,001 - $15,000
Filed
1262d ago
2019-04-08
Thomas Suozzi
BMY
Amount
$1,001 - $15,000
Filed
1262d ago
2018-04-17
Thomas Suozzi
BMY
Amount
$1,001 - $15,000
Filed
1262d ago
Recent News
Powered by Polygon.io
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?
Why Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks
CRISPR Therapeutics' Secret Weapon That Many Investors Are Overlooking
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?
Globale Daten der ROSETTA Lung-02-Studie: Ermutigende Wirksamkeit für BioNTechs und Bristol Myers Squibbs bispezifischen PD-L1xVEGF-A-Immunmodulator-Kandidat Pumitamig bei nicht-kleinzelligem Lungenkrebs
Trade Timeline
Congressional activity, newest first
Gilbert Cisneros
2025-12-19 · Purchase
$1,001 - $15,000
Julie Johnson
2025-12-18 · Sale
$1,001 - $15,000
Julie Johnson
2025-11-13 · Sale
$1,001 - $15,000
Gilbert Cisneros
2025-11-12 · Purchase
$1,001 - $15,000
Jefferson Shreve
2025-05-12 · Sale
$15,001 - $50,000
Julia Letlow
2025-04-28 · Sale
$1,001 - $15,000
Tommy Tuberville
2025-04-15 · Sale
$1,001 - $15,000
Julie Johnson
2025-04-01 · Sale
$1,001 - $15,000
Greg Landsman
2025-03-27 · Sale
$1,001 - $15,000
Julie Johnson
2025-01-15 · Purchase
$1,001 - $15,000
Valerie Hoyle
2024-10-29 · Purchase
$1,001 - $15,000
John James
2024-01-18 · Sale
$1,001 - $15,000
Greg Stanton
2023-09-26 · Purchase
$1,001 - $15,000
Daniel Goldman
2023-03-07 · Sale
$1,001 - $15,000
John Rutherford
2022-03-16 · Sale
$1,001 - $15,000
Carol Devine Miller
2021-11-10 · Sale
$15,001 - $50,000
Thomas Suozzi
2021-06-07 · Sale
$1,001 - $15,000
Thomas Suozzi
2020-07-10 · Sale
$1,001 - $15,000
Thomas Suozzi
2019-04-08 · Sale
$1,001 - $15,000
Thomas Suozzi
2018-04-17 · Purchase
$1,001 - $15,000